<DOC>
	<DOCNO>NCT01447706</DOCNO>
	<brief_summary>To determine whether combination MM-121 plus paclitaxel effective paclitaxel alone</brief_summary>
	<brief_title>A Study MM-121 With Paclitaxel Platinum Resistant/ Refractory Advanced Ovarian Cancers</brief_title>
	<detailed_description>This multicenter , open-label , randomize , Phase II study MM-121 patient platinum resistant refractory recurrent/advanced ovarian cancer . Up 210 patient randomize ( 2:1 ) receive MM-121 plus paclitaxel paclitaxel alone .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Locally advanced/metastatic recurrent epithelial ovarian cancer , fallopian tube cancer primary peritoneal cancer Received least one prior platinum base chemotherapy regimen Platinumresistant refractory Eligible weekly paclitaxel Adequate liver kidney function 18 year age Evidence active malignancy History severe allergic reaction paclitaxel drug formulate CremophorÂ®EL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Platinum-resistant</keyword>
	<keyword>Platinum-refractory</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>ErbB3</keyword>
	<keyword>Phase II</keyword>
	<keyword>locally advanced/metastatic recurrent</keyword>
</DOC>